Incretin response in Asian type 2 diabetes: Are Indians different?

Abstract

Incretin-based therapy has clearly emerged as one of the most sought out strategy in managing type 2 diabetes, primarily because they generally do not causes hypoglycemia and possess weight-neutral or weight losing properties. Efficacy-wise too, these agents, are more or less similar to commonly used drugs metformin and sulfonylureas. Interestingly, some studies recently suggested that glycemic response to these incretin-based therapies could also differ ethnicity-wise. Subsequently, meta-analysis from these studies also suggested that Asians may have better response to these incretin-based therapies. This review will be an attempt to critically analyze those studies available in literature and to address as to why East-Asians and South-Asians may have different incretin response compared to non-Asians.

• Authors: Awadhesh Kumar Singh
• Journal: Indian journal of endocrinology and metabolism (Indian J Endocrinol Metab) 2015 Jan-Feb Vol. 19 Issue 1 Pg. 30-8 ISSN: 2230-8210 [Print] India
• PMID: 25593823 (Publication Type: Journal Article, Review)